Sangamo BioSciences (SGMO) : During the past 4 weeks, traders have been relatively bearish on Sangamo BioSciences (SGMO), hence the stock is down -23.69% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.37% relative to the S&P 500. The 4-week change in the price of the stock is -22.9% and the stock has fallen -8.32% in the past 1 week.
The stock has recorded a 20-day Moving Average of 21.95% and the 50-Day Moving Average is 25.58%. Sangamo BioSciences (NASDAQ:SGMO): On Fridays trading session , Opening price of the stock was $4.46 with an intraday high of $4.52. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.36. However, the stock managed to close at $4.41, a loss of 0.68% for the day. On the previous day, the stock had closed at $4.44. The total traded volume of the day was 1,419,378 shares.
The company Insiders own 8.1% of Sangamo BioSciences shares according to the proxy statements. Institutional Investors own 67.63% of Sangamo BioSciences shares. Also, Equity Analysts at the Brokerage Firm, Janney Capital, downgrades their rating on the shares of Sangamo BioSciences (NASDAQ:SGMO). Janney Capital has a Neutral rating on the shares. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 4, 2016.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.